'Urgent action' needed to prevent resistance to antiretroviral therapy

NewsGuard 100/100 Score

"The clear pattern of increasing antiretroviral resistance in lower-income settings must be considered in the context of the worldwide HIV-control agenda," especially because "the increasing rates of antiretroviral resistance in low-income settings represent a potential threat to the emerging treatment-as-prevention strategy," Evan Wood and Julio Montaner of the BC Centre for Excellence in HIV/AIDS write in a Lancet Infectious Diseases opinion piece, adding, "Urgent action is needed." They describe steps to help lower the threat of resistance, including deploying proven preventive strategies, "early and sustained" highly active antiretroviral therapy (HAART) to prevent vertical transmission, and programs to provide HAART to 15 million people worldwide by 2015.

"A decade ago, widespread implementation of HAART in resource-limited settings seemed impossible. However, this view was wrong, and more than five million individuals infected with HIV were receiving HAART in these regions by the end of 2010," the authors write, concluding, "Now is the time to strengthen HAART roll-out initiatives to address the growing threat of antiretroviral resistance, a potential but manageable threat to the worldwide control of HIV/AIDS" (October 2011).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals increased risk of immune abnormalities in children of women with HIV